Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Myeloid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Acrocephalosyndactylia 5Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Neoplasm Metastasis 2Myeloproliferative Disorders 2Stomach Neoplasms 1Recurrence 1Oligodendroglioma 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Eosinophilia 1Endometrial Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Malignancies 1

Interventions

Oxaliplatin 53Cisplatin 52Fluorouracil 50Capecitabine 48pembrolizumab 39Leucovorin 31Docetaxel 26Trastuzumab 23Paclitaxel 20Irinotecan 20Ramucirumab 13Bevacizumab 12Cetuximab 9Radiotherapy 8Surgical Procedures, Operative 7S 1 (combination) 7Nivolumab 7Epirubicin 7Carboplatin 6olaparib 5Platinum 5Everolimus 5Sunitinib 4Mitomycin 4trastuzumab deruxtecan 3lenvatinib 3epacadostat 3bemarituzumab 3apatinib 3Saline Solution 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Stomach Neoplasms × pemigatinib × Clear all
NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡